TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M

TriSalus Life Sciences, Inc.

Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.
Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.
Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.
Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.